AAZ-A-154 (also known as Zalsupindole / DLX-001) is an innovative small molecule psychoplastogen engineered to decouple the therapeutic potential of serotonergic activation from unwanted hallucinogenic effects.
Mechanism of Action
The compound acts as a biased agonist at serotonin 5-HT₂A receptors. Unlike classical psychedelics (psilocybin, LSD), AAZ-A-154 selectively engages the intracellular TrkB/mTOR cascade responsible for synaptogenesis and structural neuroplasticity, while avoiding β-arrestin pathways associated with hallucinations. This 'functional selectivity' approach delivers neuroplastic benefits at clinically relevant doses without a psychedelic experience.
Research Data
Preclinical studies in rodents demonstrated statistically significant structural remodeling of dendritic spines in the prefrontal cortex following a single administration. Restoration of synaptic density reduced by chronic stress was observed. Antidepressant-like effects persisted for at least 7 days post single dose — a key differentiator from classical SSRIs. Cognitive impairment models showed improvements in spatial memory and executive function.
Safety Profile
In animal studies, AAZ-A-154 did not induce head-twitch response, tremor, hyperthermia, or behavioral patterns characteristic of psychedelics. Therapeutic index substantially exceeds that of classical serotonergic psychedelics.
Physicochemical Properties
White to off-white lyophilized powder. Freely soluble in DMSO (≥50 mg/mL) and acidified saline. Unstable above pH 8.5. Recommended storage: −20°C, protected from light, under inert atmosphere. Avoid freeze-thaw cycles.
BIOLABCHEMICALS